Worldwide Age at Onset of Female Breast Cancer: A 25-Year Population-Based Cancer Registry Study

Bidoli, Ettore; Virdone, Saverio; Hamdi-Chérif, M.; Toffolutti, Federica; Taborelli, Martina; Panato, Chiara

doi:10.1038/s41598-019-50680-5

Cited by 50 publications

(46 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Breast cancer onset is proportional to the median age of the underlying population at risk. 14 In this prospective study, the material median age at breast cancer diagnosis was 58.0 years, in line with most reports from Western countries with mammography screenings. 15 16 It has been reported that both young and old age at breast cancer onset indicates a poorer prognosis, compared with 'middle-aged' women, 17 18 although this observation has not been present unanimously in all studies.…”

Section: Discussionsupporting

confidence: 87%

Real-world, single-centre prospective data of age at breast cancer onset: focus on survival and reproductive history

et al. 2021

View full text Add to dashboard Cite

ObjectivesBeing either young or old at the time of breast cancer diagnosis has been suggested as an indicator of a poor prognosis. We studied the effect of age at breast cancer onset in relation to survival, focusing in particular on biological subtypes and reproductive anamnesis.Design, setting and participantsPatients with early breast cancer (n=594) treated in a Finnish University Hospital during 2003–2013 were prospectively collected and followed in median 102 months.ResultsPatients with luminal A-like breast cancer were older than the patients with luminal B-like (HER2-positive) (p=0.045) or patients with the HER2-positive (non-luminal) subtype (p=0.029). Patients ≥70 years received substantially less adjuvant chemotherapy (p=1.5×10−9) and radiotherapy (p=5.9×10−7) than younger women. Nevertheless, the estimated 10-year breast cancer-specific rates of survival were 84.2%, 92.9% and 87.0% in age groups <41 years, 41–69 years and ≥70 years, respectively, with no statistical difference (p=0.115). Survival rates were also comparable between the three age groups when assessed separately in different biological subtypes, and for patients with metastatic breast cancer there was similarly no difference between the age groups. Later menarche (p=5.7×10−8) and high parity (p=0.000078) correlated with increased age at breast cancer diagnosis, but, according to the patients’ oestrogen receptor (ER) status, only among ER-positive patients.ConclusionsDespite the suggested undertreatment of older patients, we report excellent long-term outcomes in all age groups in this prospective cohort. Later endogenous endocrine exposure may cause delay in breast cancer onset, but the exact biology behind this phenomenon is so far unclear.

show abstract

Section: Discussionsupporting

confidence: 87%

Real-world, single-centre prospective data of age at breast cancer onset: focus on survival and reproductive history

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The difference can be associated with geographical and ethic variations. It has been reported that the mean age of patients at diagnosis of breast cancer in Asian populations is lower than that in Western populations ( 27 – 29 ). A large series of mucinous cancer study in Korea also revealed that the mean age of the patients was younger than those of previous reports ( 30 ).…”

Section: Discussionmentioning

confidence: 96%

Clinicopathological and Molecular Analysis of 45 Cases of Pure Mucinous Breast Cancer

et al. 2021

View full text Add to dashboard Cite

Pure mucinous breast carcinoma (PMBC) is characterized by clusters of tumor cells floating in abundant extracellular mucin and can be classified into paucicellular (Type A) and hypercellular (Type B) subtypes. However, the clinicopathological and genomic differences between these two subtypes have not been well characterized. We retrospectively investigated the clinicopathologic features of 45 cases of surgically removed PMBC (31 Type A and 14 Type B). We also performed whole-exome sequencing (WES) in eight cases of PMBC. We found that Type B PMBC occurs at an older age and shows more aggressive clinical behavior than Type A. WES analysis revealed that HYDIN was the most frequently mutated gene in both types of PMBC. Although Type B PMBC showed a tendency toward more frequent genetic alterations, there were no statistically significant differences between the two subtypes in single nucleotide variants or insertions or deletions of bases associated with moderate or high effects. Our results provide additional evidence that PMBCs are clinicopathologically and genetically heterogeneous and lack pathognomonic genetic alterations. Further, Type B PMBC is more frequently associated with lymph node metastasis than Type A.

show abstract

“…In this large multicenter study, a pathological finding was detected in 0.8% of patients during workup of the RM specimen, including 0.2% patients with occult invasive breast cancer, confirming a low incidence of breast cancer detected during RM. Older patients were more likely to have a diagnosis of incidentally found breast cancer, though their median age (51 years) was lower than that of the overall breast cancer population (median~62 years), which is explained by the younger age structure of the study sample [10].…”

Section: Discussionmentioning

confidence: 72%

Occult Pathologic Findings in Reduction Mammaplasty in 5781 Patients—An International Multicenter Study

Kuehlmann

Vogl

Kempný

et al. 2020

JCM

View full text Add to dashboard Cite

Breast cancer is among the most commonly diagnosed cancers in the world, affecting one in eight women in their lifetimes. The disease places a substantial burden on healthcare systems in developed countries and often requires surgical correction. In spite of this, much of the breast cancer pathophysiology remains unknown, allowing for the cancer to develop to later stages prior to detection. Many women undergo reduction mammaplasties (RM) to adjust breast size, with over 500,000 operations being performed annually. Tissue samples from such procedures have drawn interest recently, with studies attempting to garner a better understanding of breast cancer’s development. A number of samples have revealed nascent cancer developments that were previously undetected and unexpected. Investigating these so-called “occult” findings of cancer in otherwise healthy patients may provide further insight regarding risk factors and countermeasures. Here, we detail occult findings of cancer in reduction mammaplasty samples provided from a cohort of over 5000 patients from 16 different institutions in Europe. Although the majority of our resected breast tissue specimens were benign, our findings indicate that there is a continued need for histopathological examination. As a result, our study suggests that preoperative imaging should be routinely performed in patients scheduled for RM, especially those with risk factors of breast cancer, to identify and enable a primary oncologic approach.

show abstract

Worldwide Age at Onset of Female Breast Cancer: A 25-Year Population-Based Cancer Registry Study

Cited by 50 publications

References 23 publications

Real-world, single-centre prospective data of age at breast cancer onset: focus on survival and reproductive history

Real-world, single-centre prospective data of age at breast cancer onset: focus on survival and reproductive history

Clinicopathological and Molecular Analysis of 45 Cases of Pure Mucinous Breast Cancer

Occult Pathologic Findings in Reduction Mammaplasty in 5781 Patients—An International Multicenter Study

Contact Info

Product

Resources

About